John Finn, PhD, the chief scientific officer of Tome Biosciences, discussed the company’s pipeline for its new technology.
John Finn, PhD
Advertisement
Articles by John Finn, PhD
John Finn, PhD, the chief scientific officer of Tome Biosciences, discussed the company’s technologies in the context of integrative gene therapy and cell therapy.
The chief scientific officer of Tome Biosciences also discussed the company’s pipeline for its new technology.
The chief scientific officer of Tome Biosciences discussed the company’s technologies in the context of integrative gene therapy and cell therapy.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CGTlive®
1
Intellia Puts Phase 3 Trials for Transthyretin Amyloidosis Gene Editing Therapy Nex-Z on Hold Following Grade 4 Liver AE
2
M. Peter Marinkovich, MD, on Integrating Gene Therapy into Clinical Practice for Dermatologists
3
Quarter Century Update: The Continued Unknowns of Cell and Gene Therapy
4
